Lysogene: loan agreement with the EIB

(CercleFinance.com) - Biopharmaceutical company Lysogene announces it has closed a 15-million-euro loan agreement with the European Investment Bank (EIB) to accelerate the development of its gene therapy platform.


This funding will support the clinical development of its main candidate drugs, including the phase 1/2 clinical trial with LYS-GM101 for the treatment of GM1 gangliosidosis and the launch of two preclinical trials with LYS-FXS01 for Fragile X syndrome.

Lysogene will receive the EIB loan in three tranches, composed of a first tranche of three million euros that can be drawn down on unconditionally and two others of five and seven million available once predefined stages have been reached.

Copyright (c) 2021 CercleFinance.com. All rights reserved.